Fig. 2.

Relationship between quantitative HER2 (H2T) and p95 expression in primary tumors and matched brain metastases. (A) H2T in primary tumors and matched brain metastases. The HERmark cutoff for HER2 positivity is indicated by the dotted lines at 17.8 RF/mm².²¹ (B) p95 in primary tumors and matched brain metastases. The previously established p95 cutoff for poor prognosis in trastuzumab-treated metastatic breast cancer¹⁷ is indicated by the dotted lines at 2.8 RF/mm². (C) Relationship between H2T and p95 expression in primary tumors. (D) Relationship between H2T and p95 expression in brain metastases. <LOD, below the limit of detection.